DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis

Information source: Muscular Dystrophy Association
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Myasthenia Gravis

Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (Drug)

Phase: Phase 0

Status: Not yet recruiting

Sponsored by: Muscular Dystrophy Association

Official(s) and/or principal investigator(s):
Matthew N Meriggioli, MD, Principal Investigator, Affiliation: University of Illinois at Chicago, 912 S. Wood St., Rm 855-N, M/C 796, Chicago IL 60612

Overall contact:
Matthew N Meriggioli, MD, Phone: 312-996-4780, Email: mmerig@uic.edu

Summary

The purpose of this study is to determine whether the drug Leukine (GM-CFS) is safe and tolerated by patients with autoimmune myasthenia gravis (MG).

Clinical Details

Official title: A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Symptomatic Autoimmune Generalized Myasthenia Gravis

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Safety of GM-CSF in patients with myasthenia gravis

The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 30 days post-treatment

The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 60 days post-treatment

The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 120 days post-treatment

Secondary outcome:

Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at 60 days

Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 120

Change from baseline in the Myasthenia Gravis Composite score at day 60

Change from baseline in the Myasthenia Gravis Composite score at day 120

Change from baseline in Manual Muscle Testing (MMT) score at day 60

Change from baseline in Manual Muscle Testing (MMT) score at day 120

Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 60

Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 120

Change from baseline in Quality of Life Assessment (SF-36) at day 60

Change from baseline in Quality of Life Assessment (SF-36) at day 120

Change from baseline in acetylcholine receptor antibody titre level at day 60

Change from baseline in acetylcholine receptor antibody titre level at day 120

Change from baseline in prednisone dose at day 60

Change from baseline in prednisone dose at day 120 Days

Detailed description: Twelve patients aged 18-80 with symptomatic generalized autoimmune MG that are not being treated with medication that suppresses their immune system, other than prednisone, will enter the study at UIC over a two year period. The study will involve a screening visit and visits at baseline and at days 5, 15, 30, 45, 60, 90, and 120. The study drug, Leukine (GM-CFS), is given by injection. Subjects will give themselves one dose of GM-CSF every day for 10 days. Study visits will include muscle testing, immunologic studies and quality-of-life studies.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Must be between 18 and 80 years of age

- Established diagnosis of myasthenia based on: the presence of fatigable weakness of

ocular, oropharyngeal, and/or limb muscles AND the presence of abnormal acetylcholine receptor binding antibodies ≥ 0. 4 nmol/l.

- Patients of childbearing potential must agree to use a medically acceptable form of

contraception defined by consistent use of oral contraceptive medications or history of tubal ligation or men who are in sexual relationship with such women during and for at least 8 weeks following completion of the study.

- Patient or designee must have the ability to self-inject investigational product

- If thymectomized, the procedure must have been performed at least one year prior to

screening.

- Dose of current anticholinesterase drugs must be constant for 2 weeks prior to

screening.

- If taking prednisone, dose must be stable for ≥4 weeks prior to screening.

Exclusion criteria:

- exclusively ocular MG (MGFA Class I)

- severe respiratory and/ or swallowing muscle weakness (MGFA Class Vb or V)

- presence of thymoma

- Must not have received plasm exchange or IVIG within 4 weeks of screening

- Must not have received immuno-modulating agents within the 4 weeks of screening,

including Azathioprine (Imuran), Cyclosporine (Sandimmune, Neoral), Mycophenolate mofetil (CellCept), GM-CSF (Filgrastim; Neupogen; pegfilgrastim, sargramostim), or any other chronic immunosuppressive agent

- History of tuberculosis or evidence of latent tuberculosis (positive PPD skin test or

a chest X-ray with evidence of tuberculosis)

- vital capacity of less than 1. 2 liters or on supplemental oxygen therapy.

- severe comorbidities including lung disease, stroke, congestive heart failure of any

severity, myocardial infarction, EKG abnormalities, uncontrolled hypertension -

(sitting systolic BP <80 or > 160 mm Hg or diastolic BP > 100 mm Hg, unstable angina pectoris, hepatic or renal disease, insulin-dependent diabetes mellitus, history of cancer (other than in-situ cervical cancer or resected, cutaneous basal cell or squamous cell carcinoma), open cutaneous ulcers, known hepatitis B surface antigen (HbsAg) or hepatitis C virus (HCV) positive, or any other concurrent medical condition, which would make it unsafe for subjects to participate in the trial or interfere with the interpretation of the results.

- Laboratories values which, at the time of the screening visit or at any time during

the study that in the opinion of the Investigator would preclude participation in the study including: serum creatinine > 2. 5 mg/dL, serum potassium < 3. 5 mmol/L or > 5. 5 mmol/L, serum aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase (ALP)> 3 times the upper limit of normal, platelet count < 100,000/mm3, WBC count < 3,000 cells/mm3, Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower limits of normal

- Receipt of a live vaccine within 3 months of screening

- participation in another investigational drug study within 90 days of screening.

- known hypersensitivity to GM-CSF or any of its components

- Known HIV-positive status or known history of any other immuno-suppressing disease.

- Any mycobacterial disease.

- Active severe infections within 4 weeks before screening visit, or between the

screening and baseline visits.

- Untreated Lyme disease.

- History of TB or TB exposure, chronic hepatitis B or hepatitis C, SLE, history of

multiple sclerosis, transverse myelitis, optic neuritis or epilepsy.

- History of recent alcohol or substance abuse (< 1 year)

- Pregnant or lactating females

- History of non-compliance with other therapies

- abnormal mental status sufficient to exclude informed consent

- History of any opportunistic infection - to include but not limited to Pneumocystis

carinii, aspergillosis, histoplasmosis, or atypical mycobacterium

- History of Sickle cell disease.

Locations and Contacts

Matthew N Meriggioli, MD, Phone: 312-996-4780, Email: mmerig@uic.edu

University of Illinois at Chicago, Department of Neurology, Chicago, Illinois 60612, United States; Not yet recruiting
Matthew N Meriggioli, MD, Phone: 312-996-4780, Email: mmerig@uic.edu
Margaret O'Connor, RN, Phone: 312-413-8605, Email: moconn@uic.edu
Additional Information

Starting date: April 2012
Last updated: March 14, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017